Belinson J L, McClure M, Badger G
Department of Obstetrics and Gynecology, Medical Center Hospital of Vermont, Burlington.
Gynecol Oncol. 1987 Oct;28(2):151-5. doi: 10.1016/0090-8258(87)90208-3.
Thirty-three patients were randomly treated with either megestrol acetate (Mg) or megestrol acetate/tamoxifen (Mg/Tx) from November, 1983, to December, 1985. Thirty-two of 33 were previously treated with platinum-based combination chemotherapy. Ten of 32 were also treated with hexamethylmelamine-based second line therapy. Doses were 160 mg/day of Mg and 20 mg/day of Tx. All patients had measurable disease. The two groups did not differ as to progression-free interval. There were no patients who demonstrated tumor regression. Overall, 39% showed stabilization of disease from 4 to 16+ months (median 8.0 months and mean 9.0 months).
1983年11月至1985年12月期间，33例患者被随机分为两组，分别接受醋酸甲地孕酮（Mg）或醋酸甲地孕酮/他莫昔芬（Mg/Tx）治疗。33例患者中有32例曾接受过铂类联合化疗。32例中的10例还接受过基于六甲蜜胺的二线治疗。Mg剂量为160mg/天，Tx剂量为20mg/天。所有患者均有可测量的疾病。两组在无进展生存期方面无差异。没有患者出现肿瘤消退。总体而言，39%的患者疾病稳定4至16个月以上（中位数8.0个月，平均9.0个月）。
